Table 2.

Primary Composite Outcome with Plasma Exchange as Compared with No Plasma Exchange.^*

Analysis	Plasma Exchange	No Plasma Exchange	Hazard Ratio (95% CI)
	no. with outcome/total no. (%)
Primary analysis†	100/352 (28.4)	109/352 (31.0)	0.86 (0.65–1.13)
Partially adjusted analysis‡	100/352 (28.4)	109/352 (31.0)	0.89 (0.68–1.17)
Per-protocol analysis	95/338 (28.1)	99/322 (30.7)	0.85 (0.64–1.13)
Analysis at 1-year follow-up	70/352 (19.9)	85/352 (24.1)	0.77 (0.56–1.06)

^*The primary composite outcome was death or end-stage kidney disease in patients with severe ANCA-associated vasculitis. CI denotes confidence interval.

^†The primary analysis was adjusted with the use of a model fitted with trial-group assignments and minimization strata as covariates.

^‡The partially adjusted analysis used a model fitted only with trial-group assignments as covariates